久久久精品欧美一区二区三区,国产欧美久久久精品影院,亚洲AV福利天堂一区二区三亚洲欧洲日韩国产AⅤ在线,亚洲成av人在线视,四虎国产精品永久地址99自拍三区一级国产片,亚洲男人的天堂久久无在线观看免费黄视频,亚洲一级特黄大片在线播放,国产成人精品区在线观看

Gene Therapy
Home > Application > Gene Therapy > Exosome

Exosome

Exosomes are subtype of extracellular vesicles, which are closed lipid bilayer structures derived from cells and secreted by almost all types of cells, including exosomes (30-150 nm), microvesicles ( 150 nm to 1 μm) and apoptotic bodies (1-5 μm). These vesicles have long been thought of as a way of loading metabolic waste, responsible for transporting waste produced by cells. Until the 1980s, when researchers were studying the development of sheep reticulocytes, they initially determined the role of some 30-150 nm vesicles and named them exosomes. Under an electron microscope, the shape of exosomes is generally cup-shaped or spherical, which protect and deliver functional macromolecules between cells, including nucleic acids, proteins, lipids and carbohydrates, and transfer their "cargo" to the recipient cells.

 

Based on years of research, the industry has recognized the potential of exosomes in a variety of applications. In current clinical trials, exosomes are used as biomarkers, cell-free therapy (exosome therapy), drug delivery systems, and anti-tumor vaccines, among others. Its sources include mesenchymal cells, T cells, and dendritic cells, as well as other engineered cell lines.

 

Exosomes have irreplaceable advantages as drug delivery vehicles, including low immunogenicity, excellent biocompatibility, and biostability. In addition to using natural exosomes without any genetic/chemical modification, there are two main ways to load payloads into exosomes: In the direct method, exosomes are prepared and purified to load therapeutic drugs (exogenous loading), while in the indirect approach, appropriate cells are genetically engineered or co-cultured with therapeutic drugs to produce engineered exosomes (endogenous loading).

 

For exogenous loading, the industry has explored various strategies to load drugs into exosomes to maximize their delivery potential, including simple incubation as well as electroporation, sonication, freeze-thaw, etc. There are often some differences between studies attributed to different parental cell biology and reagent properties. Furthermore, exosomes are inherently loaded with native proteins and nucleic acids, which greatly reduces the required loading efficiency. The correct approach to achieve optimal loading, which in turn depends to some extent on the load molecule, must be carefully selected in advance, and loading capacity, drug retention, and potential impact on exosome properties should be considered. Limitations of the direct loading strategy have limited the use of exosome-based therapies in clinical trials.

 

The creation and use of rationally and purposefully designed engineered exosomes with highly defined and reproducible properties and a known mechanism of action is a compelling alternative to naturally derived exosomes because naturally derived exosomes usually have high heterogeneity and the mechanism of action is not clear, and engineered exosomes are more feasible basis for the development of important new drugs. However, engineering methods need to achieve certain improvements in maintaining the ideal physicochemical properties of exosomes and improving loading efficiency. Yet another challenge is that most methods for exosome engineering struggle to find a balance between stable loading of the desired load and surface modification vs. maintaining exosome biocompatibility.

 

Another bottleneck in scaling exosome-based therapeutics to industrial-scale production and subsequently to the clinical trial is the production of large-scale clinical-grade exosomes. The production of exosomes is highly dependent on its parent cells, which is limited by the different ability of cells to secrete exosomes and the high difficulty and high cost of large-scale cell culture. For the pharmaceutical exosome industry, scaling up to an industrial level is still in its infancy, and it is of utmost importance to decide early on methods that will be able to produce exosomes in the required quantities and containing therapeutic payloads.

 

The inefficiency of large-scale exosome isolation methods is another obstacle to the development of clinical-grade exosomes. The number, physicochemical characteristics, and composition of exosomes released by different cell types may vary. Currently, techniques based on different principles have been used for exosome isolation, including differential/ultracentrifugation, filtration, size exclusion chromatography, immunoaffinity-based capture, polymer precipitation, etc. Although some exosome purification methods have been developed and optimized, it is still difficult to find a specific method that solves all related challenges such as low isolation efficiency, sample loss, low exosome recovery and purity, and batch-to-batch difference. Accordingly, comprehensive characterization of exosomes is also critical, especially regarding size, morphology, concentration, presence of exosomal markers/contents, and removal of contaminants.

 

Commonly used exosome isolation methods and their advantages and disadvantages

Separation   technology

Principle

Advantages

Disadvantages

Differential/ultracentrifugation based   techniques

Sequential separation based on density and   particle size

Gold   standard for exosome isolation, high throughput

Time-consuming,   operator-dependent, large volume to start, high equipment cost, and exosomes   may be damaged by high-speed centrifugation

Ultrafiltration

Particle   size

Easy to operation, good portability and   high scalability

Potential exosome degradation and lysis   (thus loss of exosomes) due to shear forces, blockage and capture of exosomes   into the filter membrane

Size exclusion chromatography

Particle size

High-purity exosomes, gravity flow retains the   structure, integrity and biological activity of exosomes (not affected by   shear stress), with good reproducibility

Time-consuming,   moderate cost of equipment, special equipment is required, and difficult to   scale up

Flow field   - flow fractionation

Particle   size

Gentle separation,   which allows for buffer exchange due to the absence of shear forces, is   especially important when isolated exosome subpopulations have potential   therapeutic applications.

May   require additional pre-concentration steps before further studies, low sample   volume, difficult to scale up

Microfluid-based technologies

Immunoaffinity, particle size and density

High efficiency, fast sample processing, high   portability, easy automation and integration

Requires large amounts of starting material to   increase yield, low sample throughput

Immunoaffinity   capture

Exosome   capture based on the use of specific exosome markers

Obtain   exosomes with high specificity and purity

High cost   of reagents, low yield, limited use

Precipitation

Solubility and dispersibility

Easy to use, does not require special   equipment, large sample processing capacity, and can be scaled.

Lack of specificity, selectivity and low purity   (other non-exosomal contaminants such as proteins and polymeric material may   co-precipitate)

 

While challenges and limitations remain, various pharmaceutical companies and start-ups have paved the way for the development of clinical-grade exosome therapeutics. A growing number of companies are focusing on developing such exosome-based therapeutics to address drug delivery for a variety of therapies, including small molecules, RNA therapeutics, proteins, viral gene therapies, and even CRISPR gene editing tool. Some of these companies are also seeking more innovative exosome engineering methods to design exosome-based therapeutics to increase drug loading and improve targeting capabilities.

 

Traditional methods of delivering RNA, protein, and chemical drugs have shown some limitations, and exosomes as drug delivery vehicles have great advantages including low immunogenicity, long-term safety, and no cytotoxicity. There are still challenges that must be overcome in terms of clinical translation, large-scale production, stable preparation, storage protocols, and quality control. Further development of cell-derived engineered exosomes and their isolation, purification, and drug loading techniques will help overcome these shortcomings. Engineered exosomes have significant commercial advantages in increasing productivity. Furthermore, by anchoring specific surface molecules to exosomes, the local concentration of exosomes in target cells or disease sites can be increased, thereby reducing toxicity and adverse reactions, and maximizing therapeutic efficacy. In the future, the industry will likely develop new types of multifunctional engineered exosomes to improve healthcare, therefore, further research is needed to explore new strategies for exosome-mediated therapies.


Related Products
Contact Us
  • Tel.: +86 021 6434 0155
  • E-Mail: marketing@duoningbio.com
  • Address: Building 30, No. 1525 Minqiang Road, Songjiang District, Shanghai
Message

Copyright ? Shanghai Duoning Biotechnology Co., Ltd. All Rights Reserved Sitemap | Technical Support: Reanod

WeChat
WeChat

Message-

Duoning Biotechnology

+86 021 6434 0155

99久久精品视香蕉蕉| 亚洲精品国产专区91在线| 欧美日韩一级片在线| 一本一道VS无码中文字幕| 四虎一区二区三区精品| 强奷乱码中文字幕熟女导航| 久久精品国产亚洲av高清漫画| 放荡的小峓子2中文字幕| 国产精品亚洲av三区国产伟业| 亚洲国产成人久久一区WWW| 国产在线视频福利资源站| 精品人妻av区天天看片| 精品一区二区三区无码免费视频| 无码人妻丰满熟妇啪啪网站| 久久精品国产99久久6动漫| 一本一道VS无码中文字幕| 乱子伦在线观看中文字幕| 亚洲中文字幕在线资源站| 国产对白老熟女进行播放| 国产日韩欧美欧美精品一区二区| 91香蕉亚洲精品人人影视| 中文字幕亚洲第一页| 亚洲Av无码乱码在线观看| AWWW在线天堂BD资源在线| 亚洲国产天堂在线观看| 国产一级a爱做片免费☆观看| 国产综合久久亚洲综合| 中文字幕久久熟女蜜桃| 国产婷婷色综合成人精品| 久久大香香蕉国产| 国产亚洲视频在线观看| 一级白嫩美女毛片免费| a毛片视频国产精品第1页| 国产美女露脸口爆吞精| 7777精品伊久久久大香线蕉| 国产人人干人人透免费看| 久久精品国产亚洲AV香蕉| 八戒八戒在线观看免费韩国| 久久青青草原国产精品免费| 国内野外强奷在线视频| 国内久久这里只有精品66|